A Study of ACP-196 (acalabrutinib) in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

Trial Identifier: ACE-CL-208
Sponsor: AcertaPharma
Start Date: March 2016
Primary Completion Date: October 2020
Study Completion Date: September 2026
Condition: CLL (Chronic Lymphocytic Leukemia)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version

Trial Locations

Country Location
BE Brugge, BE, 8000
ES Madrid, ES, 28006
FR Bordeaux, FR, 33076, FR
GB Bournemouth, GB, BH7 7DW
GB Leeds, GB, LS9 7TF
GB Manchester, GB, M20 4BX
IL Haifa, IL, 31000
US, AZ Tucson, AZ, US, 85704
US, CA Concord, CA, US, 94520
US, CA La Jolla, CA, US, 92093
US, CA Palo Alto, CA, US, 94304
US, DC Washington DC, DC, US, 20007
US, IL Chicago, IL, US, 60611
US, New York Lake Success, New York, US, 11042
US, NY New York, NY, US, 10021
US, OH Columbus, OH, US, 43210
US, TN Nashville, TN, US, 37203
US, TX Houston, TX, US, 77030
US, TX Sherman, TX, US, USA
US, WA Seattle, WA, US, 98108
US, WA Seattle, WA, US, 98122
US, WA Spokane, WA, US, 99208
US, WI Milwaukee, WI, US, 53226